【摘要】：目的:制備聚乙二醇化多西他賽白蛋白納米粒(PEG-albumin nanoparticles,PEG-DANPs),比較市售多西他賽(艾素~?,Aisu~?)、多西他賽白蛋白納米粒(DANPs)和PEG-DANPs三者對裸鼠非小細(xì)胞肺癌模型的作用。方法:分別建立BALB/c裸鼠皮下移植瘤及原位癌模型,待皮下組腫瘤體積到達(dá)120 mm3時(shí),兩組模型分別通過尾靜脈注射葡萄糖注射液,Aisu~?,DANPs和PEG-DANPs進(jìn)行治療,每7 d給藥1次,共給藥4次。在最后1次給藥2 d后,將皮下移植瘤組和原位癌組所有裸鼠全部處死,取瘤塊、肺臟、心臟、肝臟、脾送檢HE(hematoxylin-eosin staining)染色切片。另選取裸鼠32只,建立皮下移植瘤模型,分別注射上述相同藥物,持續(xù)治療直至裸鼠自然死亡,最終統(tǒng)計(jì)并繪制裸鼠生存曲線。結(jié)果:PEG-DANPs能夠有效地抑制裸鼠皮下移植瘤及原位癌的增殖,它能夠有效地控制原位癌的轉(zhuǎn)移并且延長裸鼠的生存時(shí)間。結(jié)論:PEGDANPs是一種抗腫瘤細(xì)胞效果明顯、不良反應(yīng)小的藥物,具有廣闊的應(yīng)用前景。
[Abstract]:Aim: to prepare pegylated docetaxel albumin nanoparticles (PEG-albumin nanoparticles,PEG-DANPs) and compare their effects on nude mice non-small cell lung cancer (NSCLC) models with marketable docetaxel (DANPs), docetaxel albumin nanoparticles (DANPs) and PEG-DANPs. Methods: the models of subcutaneous transplanted tumor and carcinoma in situ were established in nude mice with BALB/c. When the tumor volume of subcutaneous group reached 120 mm3, the two groups were treated by injection of glucose injection (Aisutropium) DANPs and PEG-DANPs respectively every 7 days, for a total of 4 times. After the last administration for 2 days, all the nude mice in the subcutaneous transplanted tumor group and the carcinoma in situ group were killed and HE (hematoxylin-eosin staining) staining sections were taken from the tumor mass, lung, heart, liver and spleen. Another 32 nude mice were selected to establish the tumor model of subcutaneous transplantation. The same drug was injected into the nude mice. The treatment lasted until the nude mice died naturally. Finally, the survival curve of the nude mice was calculated and drawn. Results the cell proliferation of xenografted tumor and carcinoma in situ was inhibited effectively by 1% PEG-DANPs. It could effectively control the metastasis of carcinoma in situ and prolong the survival time of nude mice. ConclusionWith PEGDANPs is an effective antitumor drug with little adverse reaction, and has a broad application prospect.
【作者單位】： 延邊大學(xué)附屬醫(yī)院;中國醫(yī)學(xué)科學(xué)院藥物研究所天然藥物活性物質(zhì)與功能國家重點(diǎn)實(shí)驗(yàn)室藥物傳輸技術(shù)及新型制劑北京市重點(diǎn)實(shí)驗(yàn)室;
【分類號】：R-332;R965

【相似文獻(xiàn)】

相關(guān)期刊論文 前9條

1 倪秉強(qiáng);張志紅;鄭良成;伍美娟;花園春;;綜合心理干預(yù)在老年晚期非小細(xì)胞肺癌化療中的應(yīng)用研究[J];徐州醫(yī)學(xué)院學(xué)報(bào);2009年06期

2 本刊編輯部;;勘誤[J];廣東醫(yī)學(xué);2012年08期

3 葛錫銳,王玨,林斯駿,余乃勛,車裕芳,顧廷;抗人肺癌的單克隆抗體LC-1(簡報(bào))[J];實(shí)驗(yàn)生物學(xué)報(bào);1989年03期

4 褚嘉佑,楊舉倫,任麗虹,范慕貞,姚樹祥,黃紹鏘;云南個舊非小細(xì)胞肺癌ras癌基因產(chǎn)物P_(21)蛋白的表達(dá)[J];昆明醫(yī)學(xué)院學(xué)報(bào);1997年04期

5 鄧群益,武培敬,陳海霞,張懷嶺;p21 ras和CD_(44)在非小細(xì)胞肺癌中的表達(dá)及其與淋巴結(jié)轉(zhuǎn)移的關(guān)系[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;1999年03期

6 ;《國際病理科學(xué)與臨床雜志》2013年第33卷總目次[J];國際病理科學(xué)與臨床雜志;2013年06期

7 朱春榮,吳德明,康蘇婭;c-erbB-2、p53、bcl-2和nm23-H_1在肺癌中的表達(dá)[J];臨床與實(shí)驗(yàn)病理學(xué)雜志;1999年03期

8 楊曉燕,劉林英,戚好文,米建新,江玲,楊敬平;肺癌神經(jīng)內(nèi)分泌標(biāo)志物研究[J];武警醫(yī)學(xué);1998年08期

9 應(yīng)漂漂;王茂峰;王巧燕;萬汝根;;LunX mRNA聯(lián)合CEA、SCCA、CYFRA21-1三項(xiàng)腫瘤標(biāo)志物診斷非小細(xì)胞肺癌的臨床應(yīng)用價(jià)值[J];實(shí)驗(yàn)與檢驗(yàn)醫(yī)學(xué);2009年06期

相關(guān)碩士學(xué)位論文 前1條

1 馮婷婷;RNA干擾MRP1的基因表達(dá)逆轉(zhuǎn)NSCLC化療耐藥的研究[D];大連醫(yī)科大學(xué);2012年

，

本文編號：2245278